Publications by authors named "Carlos Cabrera-Galvez"
MET inhibitors have demonstrated efficacy in treating patients with non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Advancements in spatial profiling technologies have unveiled the complex dynamics of the tumor microenvironment (TME), a crucial factor in cancer progression and therapeutic response. This study uses spatial profiling to investigate the effects of the MET inhibitor tepotinib on the TME in a case of locally advanced NSCLC with a METex14 skipping alteration.
View Article and Find Full Text PDFHigh-level MET amplification (METamp) is a primary driver in ∼1%-2% of non-small cell lung cancers (NSCLCs). Cohort B of the phase 2 VISION trial evaluates tepotinib, an oral MET inhibitor, in patients with advanced NSCLC with high-level METamp who were enrolled by liquid biopsy. While the study was halted before the enrollment of the planned 60 patients, the results of 24 enrolled patients are presented here.
View Article and Find Full Text PDFArticle Synopsis
- - The study focuses on detecting important genetic markers (ALK, ROS1, RET, and MET Δ) in patients with non-small cell lung cancer (NSCLC) to guide specific kinase inhibitor treatments, utilizing multiplex technology for accurate results.
- - Researchers employed nCounter, a technology that uses RNA hybridization to assess the presence of these markers in both cytological samples and biopsies, achieving higher evaluability in biopsies (90.9%) compared to cytological samples (75.0%).
- - Findings revealed specific cases of ALK and MET positivity, with patients demonstrating varying responses to treatments: one patient with MET Δ had a partial response to tepotinib, while an ALK-positive patient achieved complete response with crizotin